Cannabis for PTSD: Promising Biology, Very Little Proof It Actually Works as Treatment | Research

The takeaway

The endocannabinoid system is clearly involved in stress and fear processing, but in 2017 there was almost no rigorous clinical evidence that cannabis effectively treats PTSD.

Veterans, trauma survivors, or anyone considering cannabis for PTSD who wants to know what the science actually supports.

What the researchers found

The biological case for cannabis helping PTSD was compelling. The endocannabinoid system is deeply involved in fear extinction, stress response, and emotional memory processing — exactly the mechanisms disrupted in PTSD. Animal studies showed cannabinoids could facilitate fear extinction and reduce anxiety-like behavior.

But the clinical evidence didn't match the biology. Treatment outcome studies of whole-plant cannabis for PTSD were limited and methodologically weak. The one area with real signal was nightmares: nabilone, a synthetic cannabinoid, showed benefit for PTSD-related nightmares and sleep disruption. Beyond that, the cupboard was nearly bare.

Meanwhile, the potential harms were better documented than the benefits. Cannabis use was associated with worse outcomes in depression, anxiety, psychosis, and substance misuse — conditions that frequently co-occur with PTSD. The review found stronger evidence for marijuana's harmful effects on psychosis and substance misuse development than for its therapeutic effects on PTSD itself.

Why it matters

This review captured a tension that still exists: the biology says the endocannabinoid system should be a therapeutic target for PTSD, but giving people cannabis or THC is a blunt tool for a precise problem. The distinction between "the endocannabinoid system is involved in PTSD" and "smoking weed treats PTSD" is enormous, and this paper drew that line clearly.

The finding that evidence for harm was actually stronger than evidence for benefit was particularly important. Many veterans and trauma survivors were already self-medicating with cannabis based on the biological plausibility alone, without knowing the clinical evidence hadn't caught up.

The numbers in context

• Nabilone: showed benefit specifically for PTSD-related nightmares and sleep

• Cannabis associated with worse outcomes in comorbid conditions: depression, anxiety, psychosis, substance misuse

• Stronger evidence for cannabis causing psychosis and substance misuse than for treating PTSD

How the study worked

Systematic literature review examining preclinical and clinical evidence for cannabinoids in PTSD treatment. Covered animal models of fear conditioning, human endocannabinoid research, clinical treatment studies, and evidence of psychiatric harms. Published in Depression and Anxiety.

Who was studied

Literature review of existing studies on cannabinoids and PTSD.

What this study cannot tell us

Published in 2017, so does not capture more recent clinical trials. The review notes that existing treatment studies had significant methodological limitations. Cannot determine causation in the association between cannabis use and worse psychiatric outcomes in PTSD. Does not address different cannabis products, doses, or delivery methods.

How to read the evidence

Systematic review finding strong preclinical rationale but limited and methodologically weak clinical evidence for cannabis treating PTSD.

When this study was published

Published in 2017. Some additional clinical evidence has emerged since, but the core gap between biological plausibility and clinical proof persists.

The bigger picture

Since 2017, PTSD has become one of the most common qualifying conditions for medical cannabis programs. Some additional research has been published, but the fundamental gap this review identified — strong biological rationale, weak clinical proof — hasn't been fully closed. The nabilone-for-nightmares finding remains one of the most specific and replicated results in the entire cannabis-PTSD literature.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Would targeted cannabinoid medications work better for PTSD than whole-plant cannabis?
Does cannabis use in PTSD patients worsen psychiatric outcomes, or do people with worse symptoms self-select into cannabis use?
Could nabilone become a standard treatment for PTSD nightmares?

Common questions

Does cannabis help PTSD?

The biology is promising — the endocannabinoid system is involved in fear and stress processing. But as of this review, clinical evidence that cannabis actually treats PTSD was very limited. Synthetic nabilone showed the most specific benefit, particularly for nightmares.

Can cannabis make PTSD worse?

Possibly. This review found that cannabis use was associated with worse outcomes in conditions that commonly co-occur with PTSD, including depression, anxiety, and substance misuse. Whether cannabis causes those outcomes or people with worse symptoms use more cannabis isn't clear.

Read the original research

Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review

Depression and Anxiety, 34(3), 207-216

Depression and Anxiety is a reputable journal focusing on mental health research.

View on PubMed ↗

Citation

Steenkamp, Maria M.; Blessing, Esther M.; Galatzer-Levy, Isaac R.; Hollahan, Lisa C.; Anderson, William T.. (2017). Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review. Depression and Anxiety, 34(3), 207-216.